Abstract
Background: Besides the first-line medication for the treatment of type 2 diabetes, the growth inhibitory activity of metformin alone or in combination with conventional chemotherapeutics has been addressed on a panel of cell lines. In this study, we investigated the cytotoxicity and apoptosis of the metformin alone and in combination with dacarbazine in Raji and Ramos lymphoma cell lines.
Methods: Cell viability and apoptosis measured using resazurin assay, flow cytometry of PI stained cells and western blot analysis.
Results: Metformin showed synergistic cytotoxic effects in combination with dacarbazine, reduced cell viability, and increased apoptosis in Raji and Ramos lymphoma cells in comparison with the use of each drug alone. The activation of MAPK and SAPK/JNK (P-SAPK/JNK) were shown in both cells.
Conclusion: Overall, the result verified the synergistic effect of the metformin-dacarbazine combination, which has the value in reducing the chemotherapeutic agent dose, adverse effect and the burden of treatment for the community and patients.
Keywords: Metformin, dacarbazine, lymphoma, cytotoxic, MAPK, apoptosis, synergistic effects.
Current Molecular Pharmacology
Title:The Role of SAPK/JNK Pathway in the Synergistic Effects of Metformin and Dacarbazine on Apoptosis in Raji and Ramos Lymphoma Cells
Volume: 11
Author(s): Maryam Naserian, Elham Ramazani, Mehrdad Iranshahi and Zahra Tayarani-Najaran*
Affiliation:
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords: Metformin, dacarbazine, lymphoma, cytotoxic, MAPK, apoptosis, synergistic effects.
Abstract: Background: Besides the first-line medication for the treatment of type 2 diabetes, the growth inhibitory activity of metformin alone or in combination with conventional chemotherapeutics has been addressed on a panel of cell lines. In this study, we investigated the cytotoxicity and apoptosis of the metformin alone and in combination with dacarbazine in Raji and Ramos lymphoma cell lines.
Methods: Cell viability and apoptosis measured using resazurin assay, flow cytometry of PI stained cells and western blot analysis.
Results: Metformin showed synergistic cytotoxic effects in combination with dacarbazine, reduced cell viability, and increased apoptosis in Raji and Ramos lymphoma cells in comparison with the use of each drug alone. The activation of MAPK and SAPK/JNK (P-SAPK/JNK) were shown in both cells.
Conclusion: Overall, the result verified the synergistic effect of the metformin-dacarbazine combination, which has the value in reducing the chemotherapeutic agent dose, adverse effect and the burden of treatment for the community and patients.
Export Options
About this article
Cite this article as:
Naserian Maryam , Ramazani Elham , Iranshahi Mehrdad and Tayarani-Najaran Zahra*, The Role of SAPK/JNK Pathway in the Synergistic Effects of Metformin and Dacarbazine on Apoptosis in Raji and Ramos Lymphoma Cells, Current Molecular Pharmacology 2018; 11 (4) . https://dx.doi.org/10.2174/1874467211666180830150546
DOI https://dx.doi.org/10.2174/1874467211666180830150546 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Biology of the Enzymes that Degrade Endocannabinoids
Current Drug Targets - CNS & Neurological Disorders Polyketide Natural Products, Acetogenins from Graviola (Annona muricata L), its Biochemical, Cytotoxic Activity and Various Analyses Through Computational and Bio-Programming Methods
Current Pharmaceutical Design Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Antibacterial and Antitumorigenic Properties of Microcin E492, a Pore- Forming Bacteriocin
Current Pharmaceutical Biotechnology The Role of Intestinal Microbiota in Graft versus Host Disease
Mini-Reviews in Medicinal Chemistry The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics
Current Topics in Medicinal Chemistry Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets The Urokinase Plasminogen Activator System: Role in Malignancy
Current Pharmaceutical Design Removal of the Tag from His-tagged ILYd4, a Human CD59 Inhibitor, Significantly Improves its Physical Properties and its Activity
Current Pharmaceutical Design Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews Meet Our Associate Editor
MicroRNA Recent Progress on Tumor Missile Therapy and Tumor Vascular Targeting Therapy as a New Approach
Current Vascular Pharmacology Equipping CAR-Modified T Cells with a Brake to Prevent Chronic Adverse Effects
Current Gene Therapy Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology Bleomycin Induced Sensitivity to TRAIL/Apo-2L-Mediated Apoptosis in Human Seminomatous Testicular Cancer Cells is Correlated with Upregulation of Death Receptors
Anti-Cancer Agents in Medicinal Chemistry Identification of Two Novel Mutations in the <i>ATM</i> Gene from Patients with Ataxia-Telangiectasia by Whole Exome Sequencing
Current Genomics Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials